Dr. Jennifer Levine will be one of the first to offer Daxxify in New York City

In early September, the FDA approved Daxxify, a new injectable for smoothing facial wrinkles that are said to last longer than Botox. While Daxxify is not yet widely available on the market, it will be offered in select offices around the country during its initial launch, including that of a world-renowned facial plastic surgeon, Dr. Jennifer Levine.

With the promise of longer-lasting results, Daxxify has generated a lot of buzz. Located on the Upper East Side of Manhattan, Dr. Levine will be one of the first practices to offer Daxxify in New York City.

“[Daxxify]  contains the same core Botulinum toxin molecule as Botox, but it’s coated with a peptide.” Jennifer Levine, MD shares. “What this peptide allows it to do is to attach to the receptor more effectively and also hang around longer so this translates into longer-lasting results for patients.”

Botox has been the go-to anti-aging treatment for the last almost 20 years, a trend that has been highly linked to its benefits and results. Botox is a non-invasive cosmetic procedure and a great alternative for people looking to enhance their appearance without undergoing more complicated surgical procedures like a facelift. The results from Botox last two to four months. Daxxify may now change this.

Like Botox, Daxxify uses the same core molecule botulinum toxin, which, when injected into the face, blocks specific nerve signals from interacting with the targeted facial muscles, thus relaxing wrinkles and fine lines. It is also the only neuromodulator that does not contain any human or animal products.

Daxxify is currently the only neuromodulator that is free from human serum albumin, a protein found mostly in human blood or animal-based components.  Daxxify is also the only neuromodulator that is manufactured in the United States. Daxxify uses peptide exchange technology, which Dr. Levine explains accounts for the long-lasting results.

The proprietary stabilizing protein facilitates a better treatment interaction with its target to give longer-lasting results. The effects of cosmetic Daxxify are expected to last longer than other neuromodulators, including Botox, Xeomin, and Dysport. According to results from the phase three clinical trials performed on 2700 adults, Daxxify lasted six months on average, with 98% of the participants experiencing a significant reduction in wrinkles within four weeks of receiving Daxxify.  The onset of action is faster and smoother than the other neuromodulators.  In the clinical studies, 93% of patients that had been injected with other neuromodulators in the past preferred Daxxify.

A top 1% injector in the nation, Dr. Levine says this may significantly change the cosmetic surgery industry as it addresses an unmet need for patients and even doctors. With Botox, one needs three to four treatments per year to maintain results. However, with Daxxify, one may need just two. The effects from Daxxify are said to last anywhere between six to nine months. Another key difference between Daxxify and other neuromodulators is that Daxxify is stable at room temperature and may not require refrigeration.

As the results also last longer, Dr. Levine stresses the importance of working with a skilled and licensed injector. Unlike Botox injections, where if one is not pleased with the outcome, they may have to wait for 3 or 4 months, with Daxxify, one will have to wait for 6 to 9 months before the effects fade.